Oblique, Targovax partner on anticancer treatment

By The Science Advisory Board staff writers

June 29, 2020 -- Oblique Therapeutics and Targovax are partnering on anticancer treatment by combining their Oncos and Abiprot offerings.

The two firms will jointly investigate the technical and clinical feasibility of using Oncos oncolytic adenoviruses to deliver Abiprot antibodies to mutant RAS genes, which tend to be hard to reach.

"If successful, this would provide a first-in-class oncolytic virus candidate directly targeting RAS and demonstrate proof-of-concept for Oncos-Abiprot as a new technology platform," the companies said in a statement released June 29.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.